ArticlePloS one2020
Carotid intima-media thickness in polycystic ovary syndrome and its association with hormone and lipid profiles.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- CIMT as a sensitive indicator of cardiovascular risk in PCOS: a case-control study of sortilin and sclerostin.BMC women's health · 2026Article
- The relationship between serum galectin-3 level and echocardiographic findings in patients with polycystic ovary syndrome.BMC women's health · 2026Article
- Neutrophils and NETosis in polycystic ovary syndrome: unraveling the immuno-metabolic thromboinflammatory axis.European journal of medical research · 2026Review
- Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms.BioMed research international · 2026Review
- Diacerein and myo-inositol alleviate letrozole-induced PCOS via modulation of HMGB1, SIRT1, and NF-kB: A comparative study.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The Molecular Basis of Polycystic Ovary Syndrome and Its Cardiometabolic Correlates: Exploring the Intersection and Its Clinical Implications-A Narrative Review.Biomedicines · 2025Review
- Atherogenic ApoB-dyslipidemia, atherosclerotic cardiovascular disease, cardiac dysfunction and remodeling in high-risk young women with and without polycystic ovary syndrome: A pilot study.Frontiers in endocrinology · 2025Article
- Triglyceride-glucose index and lipid ratios in women with and without polycystic ovary syndrome: a systematic review and meta-analysis.Therapeutic advances in endocrinology and metabolism · 2025Article
- Beyond Hormones: A Systematic Review of the Risk of Cardiovascular Diseases in Polycystic Ovary Syndrome.Cureus · 2024Review
- The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment.Medicina (Kaunas, Lithuania) · 2024Review
- Carotid artery intima-media thickness in women with polycystic ovary syndrome: A cross-sectional study.International journal of reproductive biomedicine · 2024Article
- Identification of potential diagnostic genes for atherosclerosis in women with polycystic ovary syndrome.Scientific reports · 2024Article
- Article
- Possible Effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): An Update.Journal of clinical medicine · 2024Review
- Maternal self-reported polycystic ovary syndrome with offspring and maternal cardiometabolic outcomes.Human reproduction (Oxford, England) · 2024Article
- Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease.Current atherosclerosis reports · 2023Review
- Article
- Differential expression of serum mir-363-3p in patients with polycystic ovary syndrome and its predictive value for their pregnancy.BMC women's health · 2023Article
- Metformin effect on internal carotid artery blood flow assessed by area under the curve of carotid artery Doppler in women with polycystic ovarian syndrome.World journal of clinical cases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePolycystic ovary syndrome (PCOS) has been associated with an increased risk of metabolic disturbances and cardiovascular disease. Intima-media thickness of the common carotid artery (CIMT) represents a valid surrogate marker of early systemic atherosclerosis. This study aimed to investigate if CIMT is increased in PCOS patients compared to healthy controls and if there is an association with hormone and metabolic profiles.
methodsIn this prospective cross-sectional study, past medical history, anthropometrical measurements and hormonal, lipidemic and glycemic parameters were obtained in 41 PCOS patients and 43 age-matched healthy controls of similar body mass index (BMI) and frequency of smokers. B-mode ultrasound enabled CIMT measurement at the far wall of the left and right common carotid artery.
resultsPatients with PCOS showed significantly increased CIMT values compared to healthy controls (0.49±0.04mm vs. 0.37±0.04mm respectively, P<0.001). They featured a generally increased cardiovascular risk profile. Correlation analysis showed a positive association between CIMT and the adverse metabolic risk profile. The diagnosis of PCOS was the strongest predictor of CIMT, even after multiple adjustments for BMI, age and smoking status (β = 0.797, P<0.001, R2 = 0.73). A model among oligomenorrhoic patients revealed a relationship between CIMT and the suspected duration of disease (β = 0.373, P = 0.021, R2 = 0.14).
conclusionsPCOS patients are likely to feature signs of premature systemic atherosclerosis at a young age. Early exposure to adverse cardiovascular risk factors may possibly have long-term consequences on the vascular system. An early vessel screening might thus already be beneficial in these patients at a younger age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.